Bulky 1,4-benzoxazine derivatives with antifungal activity
Bioorganic & Medicinal Chemistry, ISSN: 0968-0896, Vol: 17, Issue: 11, Page: 3838-3846
2009
- 33Citations
- 27Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations33
- Citation Indexes33
- 33
- CrossRef24
- Captures27
- Readers27
- 27
Article Description
For many years the development of new azole antifungals has been quite empirically based. More recently, the publication of the crystal structure of CYP51 of Mycobacterium tuberculosis (MT-CYP51) provided new opportunities to rationalize the knowledge about antifungal action of this class of compounds.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0968089609003927; http://dx.doi.org/10.1016/j.bmc.2009.04.051; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=65549137466&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/19433362; https://linkinghub.elsevier.com/retrieve/pii/S0968089609003927; https://dx.doi.org/10.1016/j.bmc.2009.04.051
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know